| 2025 | 2024 | 2023 | 2022 | 2021 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | 6,1 M € | — | — | — | — | — | — | ||||||||||||||||
| Gross margin | 287,0 k € | +1.3% | 283,3 k € | +21.9% | 232,4 k € | -71.5% | 816,9 k € | +23.2% | 663,3 k € | +47.3% | 450,3 k € | -53.5% | 967,7 k € | -28.9% | 1,4 M € | -18.2% | 1,7 M € | — | 1,2 M € | +166.1% | 466,2 k € | -25.0% | 621,6 k € | +412.9% | -198,6 k € | -133.5% | 593,3 k € | +344.8% | 133,4 k € | |||
| EBITDA | 284,9 k € | +1.0% | 282,1 k € | +32.0% | 213,7 k € | -58.4% | 514,2 k € | +106.2% | 249,3 k € | +503.3% | -61,8 k € | -115.4% | 400,8 k € | -19.2% | 496,2 k € | +45.3% | 341,5 k € | -14.3% | 398,6 k € | +24.0% | 321,6 k € | +213.9% | -282,3 k € | -149.6% | -113,1 k € | +85.0% | -752,0 k € | -889.1% | 95,3 k € | +130.9% | -308,9 k € | |
| Operating profit | 283,2 k € | +7.5% | 263,5 k € | +2.0% | 258,3 k € | -42.8% | 451,2 k € | +165.1% | 170,2 k € | +199.2% | -171,5 k € | -170.8% | 242,2 k € | -44.6% | 437,4 k € | +116.3% | 202,2 k € | +51.0% | 133,9 k € | -15.2% | 158,0 k € | +135.2% | -448,9 k € | -65.0% | -272,0 k € | +66.8% | -820,4 k € | -1893.4% | 45,7 k € | +112.9% | -353,4 k € | |
| Profit/loss | 213,5 k € | +5.1% | 203,2 k € | +4.5% | 194,5 k € | -53.4% | 416,9 k € | +156.1% | 162,8 k € | +192.0% | -177,0 k € | -173.9% | 239,4 k € | -45.5% | 439,3 k € | +140.2% | 182,9 k € | +823.8% | -25,3 k € | -197.4% | 25,9 k € | +104.7% | -549,5 k € | -56.6% | -351,0 k € | +59.8% | -872,7 k € | -253056.8% | 345,0 € | +100.1% | -390,0 k € | |
| Equity | 2,2 M € | +11.0% | 1,9 M € | +11.7% | 1,7 M € | +12.6% | 1,5 M € | +37.0% | 1,1 M € | +36.4% | 825,9 k € | -17.6% | 1,0 M € | +31.3% | 763,6 k € | +135.5% | 324,2 k € | +129.4% | 141,3 k € | -15.2% | 166,6 k € | +18.4% | 140,7 k € | +55.9% | 90,2 k € | +36.3% | 66,2 k € | -88.3% | 563,9 k € | +79.8% | 313,6 k € | |
| Total assets | 2,4 M € | +12.2% | 2,1 M € | +9.2% | 2,0 M € | -5.5% | 2,1 M € | +32.8% | 1,6 M € | -17.3% | 1,9 M € | -10.5% | 2,1 M € | -30.5% | 3,0 M € | +10.2% | 2,7 M € | -24.9% | 3,7 M € | +7.2% | 3,4 M € | +7.4% | 3,2 M € | +1.7% | 3,1 M € | +42.6% | 2,2 M € | -13.8% | 2,5 M € | +58.9% | 1,6 M € | |
| Cash | — | — | 0,0 € | -100.0% | 354,3 k € | -0.4% | 355,8 k € | +41.1% | 252,1 k € | -36.1% | 394,9 k € | +100.0% | 197,5 k € | -10.9% | 221,7 k € | -66.2% | 655,5 k € | +91.9% | 341,6 k € | +69.7% | 201,3 k € | +27.1% | 158,4 k € | +5.6% | 149,9 k € | -63.4% | 409,7 k € | +22.6% | 334,2 k € | |||
| Debts | 236,8 k € | +24.4% | 190,3 k € | -11.2% | 214,2 k € | -58.9% | 521,3 k € | +21.7% | 428,4 k € | -59.3% | 1,1 M € | -4.0% | 1,1 M € | -51.3% | 2,3 M € | -6.7% | 2,4 M € | -31.3% | 3,5 M € | +8.3% | 3,2 M € | +7.1% | 3,0 M € | +0.2% | 3,0 M € | +42.4% | 2,1 M € | +8.0% | 2,0 M € | +53.1% | 1,3 M € | |
| Staff | 0 | 0 | 0 | 2,4 | 3,2 | 5,3 | 5,9 | 8,3 | 13,5 | 11,5 | 11,4 | 10,1 | 11,4 | 10,6 | 10,5 | 8,2 | ||||||||||||||||
Public limited company · Gent · incorporated on 22/05/2001 · 0,0 ETP
Public limited company profitable and well capitalised. Cash position declining (-100.0%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
b+pharma Belgium is a Public limited company incorporated in 2001. Its main activity is: Agents specialised in the sale of other particular products. Its registered office is in Gent.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette